At the end of 2009 IDB Holland bv, The Netherlands,decided to start the build of a new facility for the production of GMP Lu-177 trichloride.
This company was named IDB Radiopharmacy bv
In the beginning of 2011 IDB Radiopharmacy bv finished their facilities. The following GMP laboratories are currently present:
- Two GMP production laboratories (Class B) with a fully automated production line (Class A)
- One Quality Control laboratory (Class C) for determining the product specifications and isotope impurities
- One Microbiology laboratory (Class B)
All the facilities comply with GMP, EMEA and FDA regulations.
The most common use of Lutetium-177 is to label it to a DOTA complex or monoclonal antibody.
Lu-177 labelled to a DOTA complex is a radioactive labelled peptide which can be used in radiation therapy, both internally and locally. This peptide binds well to certain receptors on cells, the somatostatin-receptor. These receptors are almost exclusively found on a relatively rare kind of tumours, the neuroendocrine tumours.
To give you an overview of our recent developments, please see a couple of picture below.
For any further questions, please do not hesitate to contact our sales team at Sales@idb-holland.com